4//SEC Filing
Townsend Adam J. 4
Accession 0001127602-23-028964
CIK 0001492422other
Filed
Dec 4, 7:00 PM ET
Accepted
Dec 5, 7:29 PM ET
Size
11.4 KB
Accession
0001127602-23-028964
Insider Transaction Report
Form 4
Townsend Adam J.
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-12-01$60.50/sh−67,557$4,087,327→ 118,850 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-12-01−110,000→ 172,500 totalExercise: $15.09Exp: 2028-11-15→ Common Stock (110,000 underlying) - Sale
Common Stock
2023-12-01$61.31/sh−42,443$2,601,977→ 76,407 total - Exercise/Conversion
Common Stock
2023-12-01$15.09/sh+110,000$1,659,900→ 186,407 total
Footnotes (6)
- [F1]This is a scheduled exercise and sale from an established 10b5-1 plan.
- [F2]This transaction was executed in multiple trades at prices ranging from $60 - $60.995. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $61 - $61.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This includes 412 shares from 4/30/2023 ESPP purchase.
- [F5]This option was granted on November 16, 2018 and vests as to 25% of the shares underlying the options on the first anniversary of Mr. Townsend's date of hire, November 16, 2018, with the remaining 75% of the shares underlying the option vesting in equal monthly installments thereafter through the fourth anniversary of his date of hire, subject to continued service.
- [F6]This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.
Documents
Issuer
Apellis Pharmaceuticals, Inc.
CIK 0001492422
Entity typeother
Related Parties
1- filerCIK 0001773588
Filing Metadata
- Form type
- 4
- Filed
- Dec 4, 7:00 PM ET
- Accepted
- Dec 5, 7:29 PM ET
- Size
- 11.4 KB